Skip to main content
. 2022 Mar 8;11(6):1471. doi: 10.3390/jcm11061471

Table 2.

Outcomes in Intervention and Usual care groups.

Intention-to-Treat Cohort
Variable a All Patients
N = 91
Intervention
n = 45
Usual Care
n = 46
Readmission 29 (31.9) 14 (31.1) 15 (32.6)
ED visit 8 (8.8) 4 (8.9) 4 (8.7)
Readmission or ED visit 34 (37.4) 16 (35.6) 18 (39.1)
Costs, USD -- 5542 ± 10,970 6657 ± 16,969
Costs, USD -- 172 (127–5546) 0 (0–5667)
Costs, Intervention:Usual Care ratio b (95%CI) 0.33 (0.13–0.79)
Hypoglycemia
-Blood glucose <70 mg/dL (3.9 mmol/L) -- 5 (11) --
-Blood glucose <54 mg/dL (3.0 mmol/L) -- 2 (4) --
-Blood glucose <40 mg/dL (2.2 mmol/L) -- 1 (2) --
Number of daily SMBG tests 2.1 ± 1.5 2.4 ± 1.6 1.8 ± 1.4
Change in HbA1c at 3 months, % −0.9 (−1.6–0.2) −1.0 (−1.6–0.2) −0.9 (−1.4–0.2)
Change in HbA1c at 3 months, mmol/mol −10 (−18–2) −11 (−18–2) −10 (−15–2)
Subgroup with baseline HbA1c >7.0% All Patients
N = 69
Intervention
n = 34
Usual Care
n = 35
Readmission 19 (27.5) 8 (23.5) 11 (31.4)
ED visit 7 (10.1) 3 (8.8) 4 (11.4)
Readmission or ED visit 23 (33.3) 9 (26.5) 14 (40.0)
Costs, USD -- 3657 ± 8230 6967 ± 18,863
Costs, USD -- 154 (126–1246) 0 (0–5661)
Costs, Intervention:Usual Care ratio b (95%CI) 0.21 (0.08–0.58)
Hypoglycemia
-Blood glucose <70 mg/dL (3.9 mmol/L) -- 5 (14.7) --
-Blood glucose <54 mg/dL (3.0 mmol/L) -- 2 (5.9) --
-Blood glucose <40 mg/dL (2.2 mmol/L) -- 1 (2.9) --
Number of daily SMBG tests 2.2 ± 1.6 2.5 ± 1.6 2.0 ± 1.5
Change in HbA1c at 3 months, % −1.0 (−2.2–0.0) −1.1 (−2.2–0.0) −0.9 (−2.3–0.1)
Change in HbA1c at 3 months, mmol/mol −11 (−24–0) −12 (−24–0) −10 (−25–1)

Values are mean ± SD, median (IQR), or n (%) unless otherwise stated. IQR, interquartile range; CI, confidence interval. a Within the 30 days after hospital discharge. b Costs of 30-day readmissions, ED visits, and the intervention. SMBG, self-monitored blood glucose.